N-acetyltransferase 2 genetic variants confer the susceptibility to head and neck carcinoma: Evidence from 23 case-control studies

Tumor Biology

Volumn 35, Issue 4, 2014, Pages 3585-3595

  Zhang, Liang ^a,b   Xiang, Zhaolan ^b   Hao, Rui ^a   Li, Ru ^a   Zhu, Yi ^a  

^a CHINA AGRICULTURAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Head and neck cancer; Meta analysis; NAT2; Polymorphism; Susceptibility

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE;

ARTICLE; ASIAN; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; DIAGNOSTIC PROCEDURE; ETHNICITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEAD AND NECK CARCINOMA; HUMAN; META ANALYSIS; PRIORITY JOURNAL; SAMPLE SIZE; SENSITIVITY ANALYSIS;

ARYLAMINE N-ACETYLTRANSFERASE; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HEAD AND NECK NEOPLASMS; HUMANS; POLYMORPHISM, GENETIC; PUBLICATION BIAS; RISK;

EID: 84898819786     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1473-9     Document Type: Article

References (56)

1. Specenier P, Vermorken JB. Cetuximab: its unique place in head and neck cancer treatment. Biologics: Targets Ther. 2013;7:77-90.
2. Curado MP, Boyle P. Epidemiology of head and neck squamous cell carcinoma not related to tobacco or alcohol. Curr Opin Oncol. 2013;25:229-34.
3. Reichart PA, Nguyen XH. Betel quid chewing, oral cancer and other oral mucosal diseases in Vietnam: a review. J Oral Pathol Med. 2008;37:511-4.
4. Baez A. Genetic and environmental factors in head and neck cancer genesis. J Environ Sci Health Part C, Environ Carcinog Ecotoxicol Rev. 2008;26:174-200.
5. Fu Z, Shrubsole MJ, Li G, Smalley WE, Hein DW, Cai Q, et al. Interaction of cigarette smoking and carcinogen-metabolizing polymorphisms in the risk of colorectal polyps. Carcinogenesis. 2013;34:779-86.
6. Zhuo WL, Zhang YS, Wang Y, Zhuo XL, Zhu B, Cai L, et al. Association studies of CYP1A1 and GSTM1 polymorphisms with esophageal cancer risk: evidence-based meta-analyses. Arch Med Res. 2009;40:169-79.
7. Walker K, Ginsberg G, Hattis D, Johns DO, Guyton KZ, Sonawane B. Genetic polymorphism in N-acetyltransferase (NAT): population distribution of NAT1 and NAT2 activity. J Toxicol Environ Health Part B, Crit Rev. 2009;12:440-72.
8. Hein DW. N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine. Expert Opin on Drug Metab Toxicol. 2009;5:353-66.
9. Agundez JA. Polymorphisms of human N-acetyltransferases and cancer risk. Curr Drug Metab. 2008;9:520-31.
10. Luck H, Kinzig M, Jetter A, Fuhr U, Sorgel F. Mesalazine pharmacokinetics and NAT2 phenotype. Eur J Clin Pharmacol. 2009;65:47-54.
11. Sabbagh A, Darlu P, Crouau-Roy B, Poloni ES. Arylamine N-acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: a worldwide population survey. PLoS ONE. 2011;6:e18507.
12. Zheng Y, Li Y, Teng Y, Zhang Z, Cao X. Association of NAT2 phenotype with risk of head and neck carcinoma: a meta-analysis. Oncol Lett. 2012;3:429-34.
13. Zhuo XL, Ling JJ, Zhou Y, Zhao HY, Song YF, Tan YH. NAT2 polymorphisms with oral carcinoma susceptibility: a meta-analysis. Mol Biol Rep. 2012;39:8813-9.
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
15. Munafo MR, Clark TG, Flint J. Assessing publication bias in genetic association studies: evidence from a recent meta-analysis. Psychiatry Res. 2004;129:39-44.
16. Egger M. Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34.
17. Rosenthal R. The "file drawer problem" and tolerance for null results. Psychol Bull. 1979;86:838-641.
18. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol, Biomarkers Prev. 2000;9:29-42.
19. Hengstler JG, Arand M, Herrero ME, Oesch F. Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. Recent Results in Cancer Resh (Fortschritte der Krebsforschung Progres dans les recherches sur le cancer). 1998;154:47-85.
20. Thier R, Bruning T, Roos PH, Rihs HP, Golka K, Ko Y, et al. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes. Int J Hyg Environ Health. 2003;206:149-71.
21. Bing C, Xiaomeia C, Jinhenga L. Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects. Drug Metabol Drug Interact. 2011;26:113-8.
22. Troy JD, Weissfeld JL, Diergaarde B, Youk AO, Buch SC, Romkes M, et al. Polymorphisms in NAT2 and GSTP1 are associated with survival in oral and oropharyngeal cancer. Cancer Epidemiol. 2013;37:505-11.
23. Mukherjee S, Bhowmik AD, Roychoudhury P, Mukhopadhyay K, Ray JG, Chaudhuri K. Association of XRCC1, XRCC3, and NAT2 polymorphisms with the risk of oral submucous fibrosis among eastern Indian population. J Oral Pathol Med. 2012;41:292-302.
24. Majumder M, Ghosh S, Roy B. Association between polymorphisms at N-acetyltransferase 1 (NAT1) & risk of oral leukoplakia & cancer. Indian J Med Res. 2012;136:605-13.
25. Gajecka M, Rydzanicz M, Jaskula-Sztul R, Kujawski M, Szyfter W, Szyfter K. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma. Mutat Res. 2005;574:112-23.
26. Unal M, Tamer L, Akbas Y, Pata YS, Vayisoglu Y, Degirmenci U, et al. Genetic polymorphism of N-acetyltransferase 2 in the susceptibility to laryngeal squamous cell carcinoma. Head Neck. 2005;27:1056-60.
27. Varzim G, Monteiro E, Silva R, Pinheiro C, Lopes C. Polymorphisms of arylamine N-acetyltransferase (NAT1 and NAT2) and larynx cancer susceptibility. ORL J Otorhinolaryngol Relat Spec. 2002;64:206-12.
28. Henning S, Cascorbi I, Munchow B, Jahnke V, Roots I. Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk. Pharmacogenetics. 1999;9:103-11.
29. Chatzimichalis M, Xenellis J, Tzagaroulakis A, Sarof P, Banis K, Gazouli M, et al. GSTT1, GSTM1, GSTM3 and NAT2 polymorphisms in laryngeal squamous cell carcinoma in a Greek population. J Laryngol Otol. 2010;124:318-23.
30. Lei D, Pan X, Guo C, Xu F, Zhang L, Liu D, et al. Relationship between polymorphism of N-acetyltransferase 2 and genetic susceptibility to laryngeal carcinoma. Chin J Oncol. 2002;24:154-6.
31. Tian S, Zhang G, Yuan X, Huang M, Guo Z, Chen F, et al. The association between genetic polymorphisms of NAT1, NAT2 and susceptibility to laryngeal squamous carcinoma (LSCC) in Han population in Guangdong China. J Modern Oncol. 2013;21:1213-8.
32. Hahn M, Hagedorn G, Kuhlisch E, Schackert HK, Eckelt U. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to oral cavity cancer. Oral Oncol. 2002;38:486-90.
33. Marques CF, Koifman S, Koifman RJ, Boffetta P, Brennan P, Hatagima A. Influence of CYP1A1, CYP2E1, GSTM3 and NAT2 genetic polymorphisms in oral cancer susceptibility: results from a case-control study in Rio de Janeiro. Oral Oncol. 2006;42:632-7.
34. Hou YY, Ou HL, Chu ST, Wu PC, Lu PJ, Chi CC, et al. NAT2 slow acetylation haplotypes are associated with the increased risk of betel quid-related oral and pharyngeal squamous cell carcinoma. Oral Surg, Oral Med, Oral Pathol, Oral Radiol, and Endod. 2011;112:484-92.
35. Buch SC, Nazar-Stewart V, Weissfeld JL, Romkes M. Case-control study of oral and oropharyngeal cancer in whites and genetic variation in eight metabolic enzymes. Head Neck. 2008;30:1139-47.
36. Chen C, Ricks S, Doody DR, Fitzgibbons ED, Porter PL, Schwartz SM. N-acetyltransferase 2 polymorphisms, cigarette smoking and alcohol consumption, and oral squamous cell cancer risk. Carcinogenesis. 2001;22:1993-9.
37. Jourenkova-Mironova N, Wikman H, Bouchardy C, Mitrunen K, Dayer P, Benhamou S, et al. Role of arylamine N-acetyltransferase 1 and 2 (NAT1 and NAT2) genotypes in susceptibility to oral/pharyngeal and laryngeal cancers. Pharmacogenetics. 1999;9:533-7.
38. Katoh T, Kaneko S, Boissy R, Watson M, Ikemura K, Bell DA. A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people. Carcinogenesis. 1998;19:1803-7.
39. Majumder M, Sikdar N, Ghosh S, Roy B. Polymorphisms at XPD and XRCC1 DNA repair loci and increased risk of oral leukoplakia and cancer among NAT2 slow acetylators. Inter J Cancer (J Inter du Cancer). 2007;120:2148-56.
40. Morita S, Yano M, Tsujinaka T, Akiyama Y, Taniguchi M, Kaneko K, et al. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck squamous-cell carcinoma. Int J Cancer (J Int du Cancer). 1999;80:685-8.
41. Balaji L, Krishna BS. L VKSB: An unlikely role for the NAT2 genotypes and haplotypes in the oral cancer of south Indians. Arch Oral Biol. 2011
42. Boccia S, Cadoni G, Sayed-Tabatabaei FA, Volante M, Arzani D, De Lauretis A, et al. CYP1A1, CYP2E1, GSTM1, GSTT1, EPHX1 exons 3 and 4, and NAT2 polymorphisms, smoking, consumption of alcohol and fruit and vegetables and risk of head and neck cancer. J Cancer Res Clin Oncol. 2008;134:93-100.
43. Demokan S, Suoglu Y, Gozeler M, Demir D, Dalay N. N-acetyltransferase 1 and 2 gene sequence variants and risk of head and neck cancer. Mol Biol Rep. 2010;37:3217-26.
44. Gonzalez MV, Alvarez V, Pello MF, Menendez MJ, Suarez C, Coto E. Genetic polymorphism of N-acetyltransferase-2, glutathione S-transferase-M1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer. J Clin Pathol. 1998;51:294-8.
45. Rydzanicz M, Wierzbicka M, Gajecka M, Szyfter W, Szyfter K. The impact of genetic factors on the incidence of multiple primary tumors (MPT) of the head and neck. Cancer Lett. 2005;224:263-78.
46. Harth V, Schafer M, Abel J, Maintz L, Neuhaus T, Besuden M, et al. Head and neck squamous-cell cancer and its association with polymorphic enzymes of xenobiotic metabolism and repair. J Toxic Environ Health A. 2008;71:887-97.
47. Gara S, Abdennebi M, Chatti S, Touati S, Ladgham A, Guemira F. Association of NAT2 gene substitution mutation T341C with increased risk for head and neck cancer in Tunisia. Acta Oncol. 2007;46:834-7.
48. Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Techn Bull. 1999;8:15-7.
49. Gong C, Hu X, Gao Y, Cao Y, Gao F, Mo Z. A meta-analysis of the NAT1 and NAT2 polymorphisms and prostate cancer: a huge review. Med Oncol. 2011;28:365-76.
50. Ying XJ, Dong P, Shen B, Wang J, Wang S, Wang G. Possible association of NAT2 polymorphism with laryngeal cancer risk: an evidence-based meta-analysis. J Cancer Res Clin Oncol. 2011;137:1661-7.
51. Zhang J, Xu F, Ouyang C. Joint effect of polymorphism in the N-acetyltransferase 2 gene and smoking on hepatocellular carcinoma. Tumour Biol. 2012;33:1059-63.
52. Cox DG, Dostal L, Hunter DJ, Le Marchand L, Hoover R, Ziegler RG, et al. N-acetyltransferase 2 polymorphisms, tobacco smoking, and breast cancer risk in the breast and prostate cancer cohort consortium. Am J Epidemiol. 2011;174:1316-22.
53. Liu J, Ding D, Wang X, Chen Y, Li R, Zhang Y, et al. N-acetyltransferase polymorphism and risk of colorectal adenoma and cancer: a pooled analysis of variations from 59 studies. PLoS ONE. 2012;7:e42797.
54. Lee CH, Ko AM, Yen CF, Chu KS, Gao YJ, Warnakulasuriya S. Sunarjo, Ibrahim SO, Zain RB, Patrick WK, Ko YC: Betel-quid dependence and oral potentially malignant disorders in six Asian countries. Br J Psychiatry. 2012;201:383-91.
55. Liu L, Wagner CR, Hanna PE. Isoform-selective inactivation of human arylamine N-acetyltransferases by reactive metabolites of carcinogenic arylamines. Chem Res Toxicol. 2009;22:1962-74.
56. Galbiatti AL, Padovani-Junior JA, Maniglia JV, Rodrigues CD, Pavarino EC, Goloni-Bertollo EM. Head and neck cancer: causes, prevention and treatment. Braz J Otorhinolaryngol. 2013;79:239-47.